Corporate Member Update: Merck

Corporate Member Update: Merck

December, 2023

Merck would like to inform you that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg, in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).

Read the information here!

Become a NOS Member Today!

Platinum Corporate Members

Gold Corporate Members